Meeting
2017 ASCO Annual Meeting
Phase II study for the evaluation of efficacy of pembrolizumab (MK-3475) in patients with cancer of unknown primary.
Authors
Gauri R. Varadhachary
The University of Texas MD Anderson Cancer Center, Department of Gastrointestinal Medical Oncology, Houston, TX
Gauri R. Varadhachary , Kanwal Pratap Singh Raghav , Shubham Pant , Filip Janku , Siqing Fu , David S. Hong , Sarina Anne Piha-Paul , Rivka R. Colen , Vivek Subbiah , Jeane Painter , Apostolia Maria Tsimberidou , Bettzy Stephen , Daniel D. Karp , Lacey McQuinn , Tito R. Mendoza , Kenneth R. Hess , Funda Meric-Bernstam , Aung Naing
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research,Immunotherapy
Sub Track
Immune Checkpoint Inhibitors
Clinical Trial Registration Number
NCT02721732
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS3103)
DOI
10.1200/JCO.2017.35.15_suppl.TPS3103
Abstract #
TPS3103
Poster Bd #
192a
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A phase Ib/II study of eribulin (ERI) plus pembrolizumab (PEMBRO) in metastatic triple-negative breast cancer (mTNBC) (ENHANCE 1).
First Author: Sara M. Tolaney
Poster
2023 ASCO Annual Meeting
Phase II basket trial evaluating the efficacy of pembrolizumab (PE) combined with vorinostat (VO) in patients (pts) with recurrent and/or metastatic squamous cell carcinoma (SCC).
First Author: Christophe Le Tourneau
Poster
2022 ASCO Annual Meeting
Phase II study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
First Author: Andrea Grace Bocobo
Poster
2022 ASCO Annual Meeting
Toripalimab plus axitinib versus toripalimab or axitinib alone in patients with treatment-naive unresectable or metastatic mucosal melanoma: Interim results from a randomized, controlled, phase II trial.
First Author: Chuanliang Cui